SCHEDULE: JPMorgan Chase Discloses 5.2% Stake in Neurocrine Biosciences

JPMorgan Chase & Co. has reported a 5.2% beneficial ownership stake in Neurocrine Biosciences, Inc. common stock as of December 31, 2025.

Summary

• JPMorgan Chase & Co. reported beneficial ownership of 5,198,084 shares of Neurocrine Biosciences, Inc. common stock.
• This ownership represents 5.2% of the total class of securities.
• JPMorgan Chase & Co. holds sole voting power over 4,705,046 shares and shared voting power over 21,535 shares.
• JPMorgan Chase & Co. holds sole dispositive power over 5,196,778 shares and shared dispositive power over 1,221 shares.
• The filing was made under Rule 13d-1(b), indicating JPMorgan Chase & Co. is a parent holding company.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Subsidiaries identified as acquiring the securities include J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Asset Management (UK) Limited, J.P. MORGAN SE, JPMorgan Chase Bank, National Association, J.P. Morgan Investment Management Inc., J.P. Morgan Mansart Management Limited, and 55I, LLC.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment by a major financial entity, which is generally a positive signal of confidence in the issuer. There are no negative implications or risks disclosed within the filing itself.

Positives

• A major financial institution, JPMorgan Chase & Co., holds a significant stake (5.2%) in Neurocrine Biosciences, Inc., which can be interpreted as a vote of confidence in the company's long-term prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, suggesting a passive investment rather than an activist intent to disrupt management or strategy.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Neurocrine Biosciences, Inc. or JPMorgan Chase & Co.'s future investment intentions beyond the certification that the shares are held in the ordinary course of business.

Industry Context

The disclosure of a significant stake by a major financial institution like JPMorgan Chase & Co. in a biotechnology company such as Neurocrine Biosciences, Inc. is a routine event in the financial markets. It reflects institutional portfolio management and investment strategies rather than a specific industry trend or competitive action.

Stakeholder Impact

• Shareholders: May view the significant institutional ownership by JPMorgan Chase & Co. as a vote of confidence, potentially stabilizing or positively influencing stock perception.
• Management: The passive nature of the investment (ordinary course of business, not for control) suggests no immediate pressure or change in strategic direction from this shareholder.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant passive ownership stake by JPMorgan Chase & Co. in Neurocrine Biosciences, Inc. It does not provide new operational or financial performance data for Neurocrine Biosciences, nor does it signal any activist intent or strategic shift from JPMorgan. While institutional ownership can be a positive indicator, this filing alone does not present sufficient new information to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and continue to monitor Neurocrine Biosciences' fundamental performance and other corporate developments.

Keywords

Neurocrine Biosciences, JPMorgan Chase, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, NBI, JPM